NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Forecast & News

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings data on Thursday, October, 31st. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.10 by $0.30. The biotechnology company earned $131.17 million during the quarter, compared to analyst estimates of $97.10 million. Ironwood Pharmaceuticals had a negative return on equity of 15.83% and a negative net margin of 9.67%. The firm's quarterly revenue was up 99.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.27) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Ironwood Pharmaceuticals.

9 Wall Street analysts have issued twelve-month target prices for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $14.88 in the next year. This suggests a possible upside of 22.1% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

News coverage about IRWD stock has trended somewhat negative on Monday, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Ironwood Pharmaceuticals.

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Micron Technology (MU), Allergan (AGN), Aegean Marine Petroleum Network (ANW) and Continental Resources (CLR).

Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.80%), California Public Employees Retirement System (0.20%), Broderick Brian C (0.07%), Dupont Capital Management Corp (0.05%), Tocqueville Asset Management L.P. (0.03%) and Virginia Retirement Systems ET AL (0.01%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Broderick Brian C, Peregrine Capital Management LLC and CWM Advisors LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was purchased by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp, California Public Employees Retirement System, Tocqueville Asset Management L.P., Virginia Retirement Systems ET AL and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $12.18.

Ironwood Pharmaceuticals has a market capitalization of $1.91 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]